Alvotech_logo.jpg
Alvotech and STADA add to strategic alliance through denosumab partnership
June 11, 2024 04:00 ET | Alvotech
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...
Alvotech_logo.jpg
Alvotech og STADA útvíkka samstarf sitt með nýjum samningi um AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva
June 11, 2024 04:00 ET | Alvotech
Alvotech (NASDAQ: ALVO) og  STADA tilkynntu í dag að fyrirtækin hafi útvíkkað samstarf sitt með samningi um markaðssetningu AVT03, fyrirhugaðrar líftæknilyfjahliðstæðu við Prolia og Xgeva (denosumab)...
Alvotech_logo.jpg
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
June 11, 2024 04:00 ET | Alvotech
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...
Alvotech_logo.jpg
Alvotech gengur frá samningi við alþjóðlega fjárfesta um endurfjármögnun skulda
June 07, 2024 04:00 ET | Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið hafi gert samning um endurfjármögnun skulda við GoldenTree Asset Management, bandarískt eignastýringarfyrirtæki, sem fer fyrir hópi alþjóðlegra...
Alvotech_logo.jpg
Alvotech Announces Strategic Refinancing Agreement
June 07, 2024 04:00 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a...
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
June 05, 2024 15:12 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
“Collaboration in clinical trials ensures data integrity and safety, advancing both organizations' missions and improving patient care,” says Dr. Jennifer
Alvotech_logo.jpg
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024 08:05 ET | Alvotech
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech tekur þátt
Alvotech tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies í New York dagana 5.-6. júní 2024
May 29, 2024 08:04 ET | Alvotech
Alvotech (NASDAQ: ALVO) tekur  í heilbrigðisráðstefnu Jefferies fjárfestingabankans, í New York dagana 5.-6. júni nk. Alvotech mun halda kynningu og funda með fjárfestum og viðskiptavinum á...
Alvotech to Particip
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024 08:04 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Alvotech_logo.jpg
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024 17:15 ET | Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period...